百时美-话题@MedSci - 梅斯（MedSci）

#百时美#

60篇内容 | 2154人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1764458, encodeId=3ea01e6445899, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, objectType=article, longId=167618, objectId=e3fc16e61813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3fc16e61813, replyNumber=0, likeNumber=195, createdTime=2019-07-28, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3fc16e61813, moduleTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e3fc16e61813)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764454, encodeId=44d11e644540a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=改革开放40周年百时美施贵宝荣获双料殊荣, objectType=article, longId=154958, objectId=6ef215495894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ef215495894, replyNumber=0, likeNumber=64, createdTime=2019-01-25, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ef215495894, moduleTitle=改革开放40周年百时美施贵宝荣获双料殊荣, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6ef215495894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764456, encodeId=662e1e6445690, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, objectType=article, longId=158911, objectId=f601158911df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f601158911df, replyNumber=0, likeNumber=64, createdTime=2019-01-29, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f601158911df, moduleTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f601158911df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764453, encodeId=266c1e644534a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝欧狄沃™三季度即将登陆中国, objectType=article, longId=146555, objectId=bf9c1465557e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9c1465557e, replyNumber=0, likeNumber=62, createdTime=2018-10-20, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9c1465557e, moduleTitle=百时美施贵宝欧狄沃™三季度即将登陆中国, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bf9c1465557e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764455, encodeId=da7a1e64455fb, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=重磅突发！百时美施贵宝宣布740亿美元收购新基, objectType=article, longId=157273, objectId=0ef115e273a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef115e273a4, replyNumber=0, likeNumber=77, createdTime=2019-03-07, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef115e273a4, moduleTitle=重磅突发！百时美施贵宝宣布740亿美元收购新基, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0ef115e273a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764452, encodeId=30f91e6445214, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝荣获“2017年度创新企业”奖项, objectType=article, longId=128143, objectId=ad5a12814331, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad5a12814331, replyNumber=0, likeNumber=51, createdTime=2018-05-08, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad5a12814331, moduleTitle=百时美施贵宝荣获“2017年度创新企业”奖项, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ad5a12814331)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764451, encodeId=b74d1e64451fe, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, objectType=article, longId=94937, objectId=aed19493eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aed19493eed, replyNumber=0, likeNumber=60, createdTime=2017-08-08, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aed19493eed, moduleTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aed19493eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764448, encodeId=23a61e64448f7, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, objectType=article, longId=86946, objectId=6e9a869465e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e9a869465e, replyNumber=0, likeNumber=68, createdTime=2017-05-15, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e9a869465e, moduleTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6e9a869465e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764449, encodeId=5be11e64449b3, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）, objectType=article, longId=88389, objectId=549e88389de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=549e88389de, replyNumber=0, likeNumber=59, createdTime=2017-05-15, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=549e88389de, moduleTitle=重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=549e88389de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764450, encodeId=2eaf1e644509a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法, objectType=article, longId=94071, objectId=2032940e105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2032940e105, replyNumber=0, likeNumber=69, createdTime=2017-04-15, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2032940e105, moduleTitle=百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2032940e105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764446, encodeId=11541e64446c7, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美PD-1免疫疗法Opdivo斩获FDA第6个突破性药物资格——晚期膀胱癌, objectType=article, longId=71758, objectId=1026e1758e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1026e1758e7, replyNumber=0, likeNumber=70, createdTime=2016-10-26, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1026e1758e7, moduleTitle=百时美PD-1免疫疗法Opdivo斩获FDA第6个突破性药物资格——晚期膀胱癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1026e1758e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764447, encodeId=b1a81e6444736, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美再受挫！NICE拒绝Opdivo用于肾癌治疗, objectType=article, longId=72296, objectId=be64e229622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be64e229622, replyNumber=0, likeNumber=84, createdTime=2016-09-09, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be64e229622, moduleTitle=百时美再受挫！NICE拒绝Opdivo用于肾癌治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=be64e229622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764440, encodeId=ebdb1e644400d, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功, objectType=article, longId=63843, objectId=fe1b6384351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe1b6384351, replyNumber=0, likeNumber=88, createdTime=2016-06-04, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe1b6384351, moduleTitle=超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe1b6384351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764442, encodeId=a8951e644424a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=FDA批准百时美Opdivo（nivolumab）治疗经典型霍奇金淋巴瘤, objectType=article, longId=68639, objectId=0895686396f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0895686396f, replyNumber=0, likeNumber=68, createdTime=2016-07-13, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0895686396f, moduleTitle=FDA批准百时美Opdivo（nivolumab）治疗经典型霍奇金淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0895686396f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764441, encodeId=02131e64441a0, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功, objectType=article, longId=66959, objectId=0eb56695937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eb56695937, replyNumber=0, likeNumber=93, createdTime=2016-12-30, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eb56695937, moduleTitle=百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0eb56695937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764443, encodeId=bac51e64443b3, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美Opdivo治疗晚期非小细胞肺癌（NSCLC）具有极显著的持续总生存受益, objectType=article, longId=68857, objectId=a7e56885ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e56885ecf, replyNumber=0, likeNumber=64, createdTime=2016-11-15, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e56885ecf, moduleTitle=百时美Opdivo治疗晚期非小细胞肺癌（NSCLC）具有极显著的持续总生存受益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a7e56885ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764445, encodeId=d5001e64445e8, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=ASCO 2016：百时美免疫组合Opdivo+Yervoy一线治疗晚期非小细胞肺癌实现临床意义缓解, objectType=article, longId=70143, objectId=f4c4e01430f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4c4e01430f, replyNumber=0, likeNumber=67, createdTime=2017-02-08, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4c4e01430f, moduleTitle=ASCO 2016：百时美免疫组合Opdivo+Yervoy一线治疗晚期非小细胞肺癌实现临床意义缓解, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f4c4e01430f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764444, encodeId=b4611e64444fd, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美Opdivo获FDA批准治疗经典型霍奇金淋巴瘤，成为全球治疗血液肿瘤的PD-1免疫疗法, objectType=article, longId=68860, objectId=f36f688604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f36f688604f, replyNumber=0, likeNumber=70, createdTime=2016-08-08, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f36f688604f, moduleTitle=百时美Opdivo获FDA批准治疗经典型霍奇金淋巴瘤，成为全球治疗血液肿瘤的PD-1免疫疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f36f688604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764437, encodeId=60a51e644372e, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功, objectType=article, longId=49721, objectId=e31c49e21e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e31c49e21e9, replyNumber=0, likeNumber=85, createdTime=2015-07-25, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e31c49e21e9, moduleTitle=百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e31c49e21e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764439, encodeId=4ed71e6443994, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=3型丙肝福音！百时美丙肝新药Daklinza获FDA批准, objectType=article, longId=53837, objectId=6d795383eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d795383eb4, replyNumber=0, likeNumber=84, createdTime=2016-06-29, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d795383eb4, moduleTitle=3型丙肝福音！百时美丙肝新药Daklinza获FDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d795383eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

百时美

2020-05-29

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果

2019-07-28

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

改革开放40周年百时美施贵宝荣获双料殊荣

2019-01-25

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧

2019-01-29

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝欧狄沃™三季度即将登陆中国

2018-10-20

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

重磅突发！百时美施贵宝宣布740亿美元收购新基

2019-03-07

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝荣获“2017年度创新企业”奖项

2018-05-08

医者仁心 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查

2017-08-08

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤

2017-05-15

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）

2017-05-15

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法

2017-04-15

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美PD-1免疫疗法Opdivo斩获FDA第6个突破性药物资格——晚期膀胱癌

2016-10-26

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美再受挫！NICE拒绝Opdivo用于肾癌治疗

2016-09-09

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功

2016-06-04

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

FDA批准百时美Opdivo（nivolumab）治疗经典型霍奇金淋巴瘤

2016-07-13

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功

2016-12-30

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美Opdivo治疗晚期非小细胞肺癌（NSCLC）具有极显著的持续总生存受益

2016-11-15

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

ASCO 2016：百时美免疫组合Opdivo+Yervoy一线治疗晚期非小细胞肺癌实现临床意义缓解

2017-02-08

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美Opdivo获FDA批准治疗经典型霍奇金淋巴瘤，成为全球治疗血液肿瘤的PD-1免疫疗法

2016-08-08

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功

2015-07-25

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

3型丙肝福音！百时美丙肝新药Daklinza获FDA批准

2016-06-29

科室
- - 订阅+
  - 更多科室
工具
服务